Connect with us

Biotech

Belgian UCB completes the acquisition of RA Pharmaceutical

The biopharmaceutical company UCB from Belgium has completed the acquisition of the US-based company Ra Pharmaceuticals. The value of the cash transaction was about $2.3 billion. The Belgian multinational will increase its potential in the treatment of myasthenia gravis thanks to zilucoplan. The candidate drug zilucoplan is a synthetic macrocyclic peptide that inhibits complement factor V.

Published

on

This picture show some medical capsules.

The Belgium-based company UCB announced that it has completed the acquisition of US-based Ra Pharmaceuticals located in Cambridge, Massachusetts, which began last October. Former Ra Pharma shareholders received $48 in cash for each share of the company held at the closing, with a total cash transaction value of approximately $2.3 billion (€2.1 billion).

The closing of the acquisition also involves an update of UCB’s 2020 financial plan. For the current year, the company is targeting revenues between $5.50 billion (€5.05 billion) and $5.60 billion (€5.15 billion).

Discover the latest acquisitions in the biotech sector with our companion app, Born2Invest. Read the latest business news and be the first to know the most important stories from the world of finance.

UCB is accelerating its long-term innovation capabilities

The Belgian multinational will increase its potential in the treatment of myasthenia gravis thanks to zilucoplan, a peptide inhibitor of complement factor V (C5) currently in Phase III trials. The drug is in addition to a pipeline that already includes rozanolixizumab, a subcutaneously administered monoclonal antibody directed against FcRn (neonatal Fc receptor), also in Phase III.

UCB has also been awarded Ra Pharma’s ExtremeDiversity platform, which allows the production of synthetic macrocyclic peptides capable of combining the diversity and specificity of antibodies with the pharmacological properties of small molecules. The platform will accelerate the company’s long-term innovation capabilities.

“In the last 15 months we have taken several significant steps in our strategic growth path, in particular the Accelerate and Expand phase,” said Jean-Christophe Tellier, CEO of UCB. “This acquisition is a key part of this progress and an excellent complement to our strategy, which further increases our strong internal growth potential. Zilucoplan offers us the opportunity to become a leader in the treatment of people suffering from myasthenia gravis, an orphan neurological disease mediated by autoantibodies, with important unmet medical needs. It also strengthens our neurological and immunological areas, with both early and advanced projects, and adds a highly productive technology platform to our innovation engine,” Tellier concluded.

SEE ALSO  Is a breakthrough lung cancer treatment on the horizon?

Zilucoplan is a synthetic macrocyclic peptide

The candidate drug zilucoplan is a synthetic macrocyclic peptide that inhibits complement factor V, to be administered subcutaneously once a day, currently in Phase III trials for the treatment of myasthenia gravis, with results expected in early 2021. The molecule may potentially aspire to additional indications in immune-mediated necrotizing myopathy (IMNM), amyotrophic lateral sclerosis (ALS) and other complement-mediated disorders with unmet medical needs.

In December 2019, Ra Pharma started the phase II clinical trial of zilucoplan for the treatment of IMNM. The candidate is also one of the first drugs to be selected for evaluation in a multicenter ALS study.

An extended-release formulation of zilucoplan and a potential first-class small oral C5 inhibitor are also in the early stages of development.

Myasthenia Gravis is a chronic autoimmune condition

It is a chronic autoimmune condition in which autoantibodies attack acetylcholine receptors at the neuro-muscular junction, interrupting the transmission of nerve stimuli to muscles and causing muscle weakness and fatigue. The disease affects men and women of all ages and races in the same way.

Myasthenia gravis is a rare disease that affects nearly 200,000 patients in the United States, the European Union and Japan. Sufferers may experience a number of symptoms including drooping eyelids and double vision, as well as severe muscle weakness that can become potentially lethal if it gets to the breathing muscles.

__

(Featured image by stevepb via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in , a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Angelique Moss is a London-based entrepreneur, writer, and traveller. The world of business, finance, and technology, is her preferred cup of tea. She also writes about the developments and discussions on health, art, luxury and media. A top writer for several Medium publications, she has published hundreds of widely read articles on investing, stocks, global markets, cannabis, and technology for multiple platforms. She is also interested in culture, history, and social affairs.